FMP
Emmaus Life Sciences, Inc.
EMMA
PNK
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
0.0116 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Willis C. Lee M.S.
sector
Healthcare
industry
Biotechnology
exchange
PNK
Description
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus ...
CIK
0000822370
ISIN
US29137T1016
CUSIP
29137T101
Address
21250 Hawthorne Boulevard
Phone
310 214 0065
Country
US
Employee
51
IPO Date
May 9, 2000
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
EMMA Financial Summary
CIK
0000822370
Exchange
PNK
Industry
Biotechnology
Sector
Healthcare
CUSIP
29137T101
ISIN
US29137T1016
Country
US
Price
0.01
Beta
6.61
Volume Avg.
30.06k
Market Cap
740.84k
Shares
-
52-Week
1.0E-4-0.13215
DCF
1.15
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.23
P/B
-
Website
https://www.emmausmedical.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EMMA News
It looks like there's no news available.
